# Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients

> **NCT03795350** · PHASE1 · TERMINATED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 19 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease
- Asthma

## Interventions

- **DRUG:** Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide

## Key facts

- **NCT ID:** NCT03795350
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-14
- **Primary completion:** 2020-04-03
- **Final completion:** 2020-04-03
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** In light of the cessation of non-essential clinical activities at CPU due to the COVID-19 pandemic, the sponsor has determined to terminate the study early.
- **Last updated:** 2022-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03795350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03795350, "Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03795350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*